Brief: Eagle Pharmaceuticals Gets FDA Approval For PEMFEXY Additional Indication
19/12/2022 11:53
Dec 19 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS RECEIVES FDA APPROVAL FOR ADDITIONAL
INDICATION FOR PEMFEXY® IN COMBINATION WITH PEMBROLIZUMAB AND
PLATINUM CHEMOTHERAPY
Source text for Eikon: ID:nGNX8hskXN
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq